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Tumor necrosis factor-alpha (TNF) Is recognized as a principal mediator of a variety of
pathophysiologic and immunologic events. Llpopolysaccharide (LPS) challenge, either in
vitro or in vivo, results in significant TNF production. In this study we present data
demonstrating LPS-lnduced TNF mRNA expression and bioactlvlty using an In vitro tis-
sue system of whole blood (WB). The kinetics of LPS-induced TNF production by WB was
signifIcantly accelerated as compared to isolated cultured peripheral blood monocytes
(PBM). At post-LPS challenge, plasma from WB demonstrated a rapid rise in TNF bloac-
tivity, peaking by 4 hr (1,021 units/mI/i 06 cells), plateauing between 4 and 8 hr, and then
decreasing over the next 16 hr. In contrast, the highest measured TNF bioactlvity from
PBM did not occur until the 24-hr time-point (175 unIts/mI/b6 cells). Whole blood buffy-
coat TNF mRNA was assessed by Northern blot analysis, and demonstrated significant
TNF mRNA accumulation at 1 hr and a peak 2 hr post-LPS challenge. By 8 hr TNF mRNA
was undetectable. Concomitant administration of LPS with either prostagiandin E2
(106M) or Dexamethasone (106M) resulted In significant suppression of LPS-induced
TNF production. This data supports WB as a useful in vitro medium for the molecular and
cellular analyis of TNF. As specialized connective tissue, WB may provide an important
environment to study the pharmacologic manipulation of TNF mRNA and bloactivity.
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INTRODUCTION
Tumor necrosis factor-alpha (TNF) is a mononuclear
phagocyte-derived cytokine that may orchestrate a vari-
ety of physiological and immunological events [1 ,2]. At
the cellular level, TNF has diverse effects on a variety of
cell types and serves as an effective signal for cell-to-cell
communication [3-9]. At the systemic level, TNF plays
a significant role in promotion of cachexia and mediation
of septic shock [10,11]. Human-derived TNF has been
studied both in vivo and in vitro post-lipopolysaccharide
(LPS) challenge [12,13]. The production of human TNF
has been documented in vivo both clinically, septic pa-
tients [13], and experimentally, after normal subjects re-
ceived systemic LPS [14]. In vitro the majority of data
regarding the synthesis and regulation of human TNF has
been generated using primary cells in culture or tumor
lines [12,15]. Although these systems have provided
valuable approaches in studying the production and reg-
ulation of TNF, they both have inherent limitations. In
order to bridge the in vivo and in vitro TNF studies, we
have utilized whole blood as a system to assess the pro-
duction and mRNA expression of human TNF. Since
blood is defined as a specialized circulating connective
tissue that communicates with other organs/tissues [16],
we have used this medium to: 1) examine the production
of biologically active TNF and compare this with TNF
levels from monolayers of peripheral blood monocytes,
2) assess TNF mRNA expression from the cellular con-
stituents of intact whole blood, and 3) evaluate pharma-
cologic regulation of TNF bioactivity.
MATERIALS AND METHODS
Recovery of Whole Blood and Isolation of
Peripheral Blood Monocytes
Peripheral blood was obtained by venipuncture from
healthy human volunteers (n = 9). Five ml of heparin-
ized (50 USP units/ml) whole blood (WB) was aliquoted
into 15 ml conical tubes. Peripheral blood monocytes
(PBM) from WB diluted 1:1 with normal saline were
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separated by density centrifugation on Ficoll-Hypaque
(Pharmacia, Piscataway, NJ). Isolated mononuclear cells
were resuspended in sterile RPMI-l640 (Whitaker Bio-
medical Products, Whitaker, CA), 1 mM glutamine, 25
mM HEPES, 100 units penicillin, 100 .ag streptomycin!
ml (Hazelton Research Products, Denver, PA) (complete
media) and washed three times. Differential cell counts
and viability analyses by trypan-blue exclusion were
conducted for PBM. Peripheral blood monocytes (106
cells/mI) were plated in 10 ml volumes in 100 mm cul-
ture plates (Costar, Cambridge, MA) and incubated for 1
hr at 37#{176}Cin 95% air and 5% CO2. Cells were washed
twice with complete media for adherence enrichment.
Total and differential cell counts for WB were per-
formed. Whole blood in 15 ml conical tubes was stim-
ulated in a dose or kinetic fashion with specific reagents,
then placed on a rocker at 37#{176}Cin 95% air and 5% CO2.
At specified times, WB was centrifugated at 600g for 5
mm. Plasma and buffy-coat (cells) were isolated for bio-
assay and nucleic-acid extraction, respectively. Cell-free
supernatant from cultured PBM was removed for TNF
assay and the adhered cells extracted for mRNA analy-
sis.
Reagents
Prostaglandin E2 (POE2) was the generous gift of the
Upjohn Company. Stock PGE2 was prepared at a con-
centration of l02M in ethanol. Dexamethasone (Dex;
Sigma Chemical Co., St. Louis, MO) stock was pre-
pared at a concentration of l02M in dimethyl sulfoxide
(DMSO). Serial dilutions of POE2 and Dex were pre-
pared in complete media. Lipopolysaccharide (Escheri-
chia co/i Olll:B4; Sigma Chemical Co.) stock was pre-
pared at a concentration of 200 i.g/ml in complete
media.
Tumor Necrosis Factor Bioassay
Tumor necrosis factor bioactivity was measured in
both the cell-free supernatants and plasma. Bioactivity of
TNF was monitored using a semi-automated WEHI 164
subclone 13 fibrosarcoma lytic assay. WEHI cells were
suspended 5 X lO in 100 l of RPMI-1640, 10% fetal
calf serum, 1 mM glutamine, 0.5 g/ml actinomycin D,
and plated in 96-well culture plates. Samples were seri-
ally diluted and 100 pA added to each well. Plates were
allowed to incubate for 20 hr at 37#{176}Cin 95% air and 5%
CO2. This was followed by the addition of 20  of MT1’
tetrazolium (5 mg/mi; Sigma Chemical Co.) for an ad-
ditional 4 hr. One hundred fifty microliters of superna-
tant fluid was removed from each well and replaced with
100 pA of isopropanol-0.04 N HCL to dissolve the tet-
razolium crystals. Culture plates were then read in a
microELISA reader at 540 nm. Units of TNF were de-
fined using an internal standard of human recombinant
TNF with a specific activity of 22 units/ng protein (Cetus
Corp., Emeryville, CA). To allow comparison of TNF
bioactivity between different experiments or between
WB and PBM, TNF was further standardized to either
the number of adherent monocytes (PBM) or absolute
quantity of monocytes derived from the total cell and
differential counts from WB. Rabbit anti-human TNF
neutralizing antibody was used to establish specific TNF-
induced cell lysis.
Northern Blot Analysis of TNF mRNA
Total RNA from PBM and WB buffy-coats was iso-
lated as previously described [17]. Briefly, at specific
time-points PBM and WB buffy-coats were placed into a
solution of 25 mM Tris, pH 8.0, containing 4.2 M guani-
dine isothiocyanate, 0.5% sarkosyl, and 0. 1 M 2-mer-
captoethanol. After homogenization, an equal volume of
100 mM Tris, pH 8.0, containing 10 mM EDTA and
1 .0% SDS was added and the mixture was extracted with
chloroform-phenol and chloroform-isoamyl alcohol. The
RNA was alcohol precipitated and the pellet dissolved in
10 mM Tris/0.l mM EDTA (TE) buffer with 0.1% sar-
kosyl. RNA (10 p.g/lane) was separated using formalde-
hyde/l% agarose gels and transblotted to nitrocellulose.
The blot was baked, prehybridized, and hybridized with
32P..5’ end-labeled synthetic oligonucleotide probe for
human TNF. The nucleotide sequence for TNF was
the 25-mer 5 ‘-GGT-CAC-CCT-TCT-CCA-GCT-GGA-
AGA-C-3’ [18]. Blots were washed and autoradio-
graphed with intensifying screens. Relative sensitivity of
autoradiographs were quantitated using laser densitome-
try (Ultrascan XL, LXB Instruments, Inc., Houston,
TX). Equivalent amounts of total RNAIgel were assessed
by monitoring 28S and 18S rRNA.
RESULTS
LPS-lnduced TNF Bioactivity From WB and PBM
The classical stimulus for induction of TNF at both the
cellular and molecular level is LPS [1]. This stimulus
was utilized as a primary challenge in our experiments.
We first examined the dose-response of LPS-induced
TNF bioactivity from both WB and PBM. Whole blood
and PBM monolayers were incubated for 3 hr post-LPS
(10 pg/mI to 10 pg/ml) challenge. Concentrations of LPS
above 10 ng/ml resulted in significant increases in TNF
bioactivity from both WB and PBMs. TNF bioactivity
was noted to be maximal with 10 pg/ml of LPS (data not
shown). We next examined the kinetics of TNF produc-
tion from WB and PBM after LPS stimulation. Both WB
and PBM were challenged with 10 p.g/ml LPS and either
plasma or cell-free supernatant was removed at the des-
ignated times. As depicted in Figure IA, kinetic analysis
of LPS-induced TNF bioactivity from WB was deter-
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Fig. 1. The kinetic analysis of LPS-induced TNF bloactivity
from WB and PBM. Whole blood and PBM were both challenged
with LPS (10 .tg/ml) and either plasma or cell-free supernatants
were Isolated and analyzed for TNF production at designated
times. A: Whole blood TNF bloactivlty from 9 subjects was sig-
nificant at 1 hr (107 ± 17 units/ml/i0#{176} cells), peak bloactivity at
4 hr (1,021 ± 128 units/mI/b 06 cells), with a plateau from 4 to 8
hr followed by a gradual declIne (43%) over the next 16 hr to a
TNF level of 585 ± 73 units/mi/b 06 cells at 24 hr. Each time-poInt
was statistically different from each other except 4 and 8 hr (P
<0.05). In contrast, B isa representative kinetic analysis of TNF
bioactlvity from PBM (n = 4). TNF bloactlvity was found to rise
gradually throughout the study period with maximal TNF activ-
ity achieved at 24 hr post-LPS challenge (175 units/mI/i 06 cells).
mined from nine subjects. TNF levels were significant at
1 hr (107 ± 17 units/ml/l06 cells), peaking at 4 hr (1,021
± 128 units!mlIlO6 cells) with a plateau in bioactivity
between 4 and 8 hr. This plateau in bioactivity was fol-
lowed by a gradual decline (43%) over the next 16 hr to
a TNF level of 585 ± 73 units/ml/l06 cells at 24 hr.
Cellular viability after 24 hr was established by exclusion
of trypan-blue from buffy-coat cells (>90%). To exclude
a plasma inhibitor of TNF, plasma from time-points after
8 hr were treated with exogenous recombinant human
TNF. Plasma from these time-points failed to inhibit ex-
ogenous TNF. In contrast, Figure lB is a representative
kinetic analysis of TNF bioactivity from PBM monolayer
(n = 4). TNF bioactivity was found to rise gradually
throughout the study period with maximal TNF activity
being achieved at 24 hr post-LPS challenge (175 units!
ml/l06 cells). The 8 hr time-point from PBM monolayer
represented <50% of the maximal TNF response at 24
hr.
WB-Derived TNF mRNA
To examine TNF gene expression from WB, we next
assessed LPS-induced TNF mRNA accumulation in a
kinetic fashion from WB (buffy-coat cells). Whole blood
(5 ml) was stimulated with LPS (10 ig/ml) at time zero,
and total RNA from the buffy-coat was extracted at spec-
ified times. Figure 2 demonstrates the Northern blot
analysis of WB-derived TNF mRNA accumulation at
specific times post-LPS addition. Each lane represents
10 p.g of total RNA loaded per well. TNF mRNA accu-
mulation was significant at 1 hr, with a peak in TNF
mRNA occurring at 2 hr post-LPS challenge. TNF
mRNA rapidly decayed after 2 hr, with essentially base-
line levels achieved by 8 hr (n = 4).
Pharmacologic Suppression of TNF
Bloactivity From WB
To establish the efficacy of WB as a tool for monitor-
ing pharmacologic manipulation of TNF production,
both POE2 and Dex were evaluated for their ability to
suppress WB-derived TNF bioactivity. POE2 and Dex at
a concentration of l06M have been shown to inhibit
mononuclear phagocytic cell TNF synthesis in vitro
[17,19]. Whole blood (5 ml) was incubated for 3 hr in the
presence of either LPS (10 p.g/ml) alone, POE2 (106M)
concomitant with LPS, Dex (l06M) concomitant with
LPS, or media alone. As shown in Figure 3, concomitant
administration of either POE2 or Dex resulted in a 91%
and 80% suppression of LPS-stimulated WB-derived
TNF bioactivity (n = 3), respectively. Neither PGE2 nor
Dex in concentrations utilized in these experiments was
found to inhibit the activity of exogenous recombinant
TNF in our WEHI bioassay.
DISCUSSION
Tumor necrosis factor-alpha (TNF) is increasingly rec-
ognized for its pleiotropic effects in immune and patho-
physiologic events. It appears to be an essential cytokine
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Fig. 2. Northern blot analysis of WB-derived TNF mRNA accu-
mulation. Whole blood was stimulated with LPS (10 g/ml) and
buffy-coat nucleic-acid was extracted in a kinetic fashion. TNF
mRNA accumulation was significant at 1 hr, peaking at 2 hr
post-LPS challenge, and rapidly declined to baseline levels by 8
hr. Ten g total RNA was load per lane.
chestrating a variety of local acute and chronic inflam-
matory processes [1]. The antithesis of local TNF pro-
duction is its presence systemically, representing an
essential mediator of septic shock or chronic cachexia
[1]. TNF has been extensively investigated as an impor-
tant inflammatory protein, yet relatively little is known
regarding its synthesis and regulation in human cells.
The production of human TNF in vivo has been mea-
sured in the serum of septic patients or normal subjects
who have received intravenous LPS [13,14]. In vitro,
both human TNF production and regulation have been
evaluated only in cell systems, such as monolayers of
blood monocytes or alveolar macrophages [12,15]. A
tissue system, simulating the complexity of an in vivo
system, would prove useful to assess the dynamics of
TNF production and gene expression.
In this present study we demonstrate that intact whole
blood can be utilized as a tissue system to examine the
Fig. 3. PGE2 and Dex suppression of LPS-induced TNF bloac-
tivity from WB (n = 3). Whole blood was stimulated wIth either
LPS (10 ig/ml), PGE2 (bO#{176}M),and LPS (10 g/ml), or Dex
(10#{176}M)and LPS (10 g/ml) and the plasma analyzed for TNF
bioactivity at 3 hr. Both PGE2 and Dex demonstrated significant
suppression of LPS-induced TNF production (P < 0.05).
molecular and cellular expression of TNF. Our findings
show that LPS in either a dose-dependent or kinetic fash-
ion results in TNF production from WB. The peak in
TNF production from LPS-treated WB was several mag-
nitudes greater than PBM, standardized to equivalent
numbers of monocytes. This discrepancy in TNF pro-
duction between WB and PBM was not explained by
lymphocyte-derived TNF, as LPS does not induce the
expression of lymphocyte-derived TNF [15]. The peak in
WB kinetic expression of TNF was shifted markedly
toward the left as compared to PBM. TNF peaked at 4 hr
in WB followed by a plateau in activity from 4 to 8 hr
and then declined over the next 16 hr.
In contrast, the peak in TNF from PBM was delayed
until 24 hr post-LPS. The difference in TNF kinetics
between WB and PBM was not explained by altered
cellular viability, as WB buffy-coat cells and PBM were
found to have similar viability at 24 hr. The decrease in
WB TNF after 8 hr was not due to a WB-derived TNF
plasma inhibitor/protease. Plasma isolated from time-
points after 8 hr failed to inhibit exogenous TNF in our
bioassay. A plausible explanation for the decline in WB
TNF production from 8 to 24 hr may be explained by the
internalization of TNF after interaction with its cell-as-
sociated receptor [20-22]. In additional studies we dem-
onstrate that both POE2 and Dex inhibited LPS-induced
TNF from WB. This system provides a novel model to
determine the efficacy of pharmacologic alteration of cy-
tokines in WB. This aspect is important, since many
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pharmacologic agents are less active in vivo yet retain
activity in a less complex system such as cell culture.
The use of whole blood as a model system, with the
complexity of tissue, has enormous potential for the
study of cytokine regulation and synthesis. The cellular
and molecular level of cytokine regulation can be studied
by monitoring specific mRNA and protein bioactivity in
the huffy-coat and plasma, respectively. Furthermore,
blood recovered from patients receiving a specific phar-
macologic agent can be assessed to determine alterations
in both the production of inflammatory cytokines and
expression of cytokine mRNA. Regulation of cytokines
in whole blood by various substances is relevant and may
have significant implication for the use of this system
prior to the analysis of drug effects in vivo.
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